FDA panel backs Allergan’s night-time urination nasal spray
US regulatory advisors are backing clearance of Allergan’s SER120, a low-dose nasal formulation of desmopressin designed to treat night-time urination.
Read More
Tag: advisory panel
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
